Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro‐oesophageal reflux disease and peptic ulcer disease

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2003-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1365-2036.2003.01756.xPMID 12969082
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results

  2003cited by this paper
• Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis

  2002cited by this paper
• Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis

  2002cited by this paper
• A randomized, double‐blind, comparative study of standard‐dose rabeprazole and high‐dose omeprazole in gastro‐oesophageal reflux disease

  2002cited by this paper
• A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial

  2002cited by this paper
• Pantoprazole versus lansoprazole in French patients with reflux esophagitis.

  2001cited by this paper
• Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial

  2001cited by this paper
• Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety

  2001cited by this paper
• Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis

  2001cited by this paper
• Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients

  2001cited by this paper
• Esomeprazole 20 mg maintains symptom control in endoscopy‐negative gastro‐oesophageal reflux disease: a controlled trial of ‘on‐demand’ therapy for 6 months

  2001cited by this paper
• The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6‐month, randomized, double‐blind, placebo‐controlled study of efficacy and safety

  2001cited by this paper
• A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction

  2001cited by this paper
• Rabeprazole, 20 mg Once Daily or 10 mg Twice Daily, Is Equivalent to Omeprazole, 20 mg Once Daily, in the Healing of Erosive Gastrooesophageal Reflux Disease

  2000cited by this paper
• Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial

  2000cited by this paper
• Rabeprazole Versus Omeprazole in Preventing Relapse of Erosive or Ulcerative Gastroesophageal Reflux Disease

  2000cited by this paper
• Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease.

  2000cited by this paper
• The proton-pump inhibitors: similarities and differences.

  2000cited by this paper
• Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro‐oesophageal reflux disease (GERD) who are resistant to conventional‐dose lansoprazole therapy—a prospective, randomized, multi‐centre study

  2000cited by this paper
• Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro‐oesophageal reflux disease

  2000cited by this paper
• Double‐blind, placebo‐controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro‐oesophageal reflux disease

  1999cited by this paper
• Lansoprazole versus omeprazole for duodenal ulcer healing and prevention of relapse: a randomized, multicenter, double-masked trial.

  1999cited by this paper
• Low‐dose lansoprazole provides greater relief of heartburn and epigastric pain than low‐dose omeprazole in patients with acid‐related dyspepsia

  1999cited by this paper
• Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.

  1999cited by this paper
• Double‐blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2‐receptor antagonists

  1999cited by this paper
• Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study

  1999cited by this paper
• A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis

  1998cited by this paper
• Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group.

  1998cited by this paper
• Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: a long‐term comparative study

  1998cited by this paper
• Gastro‐oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole

  1998cited by this paper
• Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer—a European multicentre study

  1998cited by this paper
• Daily omeprazole surpasses intermittent dosing in preventing relapse of oesophagitis: a US multi‐centre double‐blind study

  1997cited by this paper
• Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice.

  1997cited by this paper
• Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis.

  1996cited by this paper
• Comparison of once-daily doses of omeprazole (40 and 20 mg) and placebo in the treatment of benign gastric ulcer: a multicenter, randomized, double-blind study.

  1996cited by this paper
• Assessing the quality of reports of randomized clinical trials: is blinding necessary?

  1996cited by this paper
• Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group.

  1996cited by this paper
• Lansoprazole 30mg versus omeprazole 40mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial)

  1996cited by this paper
• Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Dutch Study Group.

  1996cited by this paper
• Users' guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group.

  1995cited by this paper
• Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration—a multicentre study

  1995cited by this paper
• Pantoprazole versus omeprazole in the treatment of acute gastric ulcers

  1995cited by this paper
• Users' Guides to the Medical Literature: IX. A Method for Grading Health Care Recommendations

  1995cited by this paper
• A double‐blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis : a multicentre trial

  1995cited by this paper
• Lansoprazole versus omeprazole in active duodenal ulcer. A double-blind, randomized, comparative study.

  1995cited by this paper
• Users' guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group.

  1994cited by this paper
• Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial.

  1993cited by this paper
• Users' guides to the medical literature.

  1993cited by this paper
• Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study.

  1992cited by this paper
• Rules of evidence and clinical recommendations on the use of antithrombotic agents.

  1992cited by this paper
• Rules of evidence and clinical recommendations on the use of antithrombotic agents.

  1989cited by this paper
• Rules of Evidence

  1978cited by this paper

• Updating understanding of real-world adverse events associated with omeprazole

  2025cites this paper
• Effect of proton pump inhibitors compared to histamine-2 receptor antagonists on bleeding management and wound healing after endoscopic mucosal resection or endoscopic submucosal dissection: A meta-analysis of randomized clinical trials.

  2024cites this paper
• Recommendations for prevention and treatment of Esophago-Gastro-Entero-Colopathies induced by non-steroid anti-inflammatory drugs (NSAIDs) - 2025

  2024cites this paper
• Role of Proton Pump Inhibitors in the Management of Peptic Ulcer

  2023cites this paper
• Long-term Proton Pump Inhibitor Administration Caused Physiological and Microbiota Changes in Rats

  2020cites this paper
• Foregut Surgery: Achalasia, Gastroesophageal Reflux Disease and Obesity

  2020cites this paper
• Inhibitory protonové pumpy – nové molekuly , nové poznatky

  2020cites this paper
• Medical Treatment of GERD

  2019cites this paper
• RECOMMENDATIONS FOR THE PREVENTION AND TREATMENT OF ESOPHAGO- GASTRO- ENTERO-COLOPATHY INDUCED BY NONSTEROIDAL ANTIINFLAMMATORY DRUGS “NSAID”

  2018cites this paper
• Potential Gastroprotective Activity of Rice Bran (Oryza sativa L.) Extracted by Ionic Liquid-Microwave-Assisted Extraction against Ethanol-Induced Acute Gastric Ulcers in Rat Model.

  2018cites this paper
• Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection

  2018cites this paper
• International Consensus on Guiding Recommendations for Management of Patients with Nonsteroidal Antiinflammatory Drugs Induced Gastropathy-ICON-G

  2018cites this paper
• ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats

  2018cites this paper
• A study of CYP2C19*2, *3 and *7 in different Sudanese ethnic groups and their response to omeprazole based triple therapy in Khartoum, Sudan 2016-2017

  2018cites this paper
• Adverse Effects of Proton Pump Inhibitors on Platelet Count: A Case Report and Review of the Literature

  2018cites this paper
• Gastroesophageal reflux disease: A clinical overview for primary care physicians.

  2017cites this paper
• Proton pump inhibitors

  2016cites this paper
• Acid-reducing vagotomy is associated with reduced risk of subsequent ischemic heart disease in complicated peptic ulcer

  2016cites this paper
• Practical considerations in the management of proton-pump inhibitors.

  2016cites this paper
• Potential effects of rational prescribing on national health care spending: More than half a billion dollars in annual savings.

  2016cites this paper
• Consideraciones prácticas en el manejo de los inhibidores de la bomba de protones

  2016cites this paper
• Potential effects of rational prescribing on national health care spending

  2016cites this paper
• Effets potentiels d’un modèle rationnel de prescription sur les dépenses nationales en santé Plus d’un demi-milliard de dollars en économies annuelles

  2016cites this paper
• The Indications, Applications, and Risks of Proton Pump Inhibitors.

  2016cites this paper
• The effect of financial and educational incentives on rational prescribing. A state-space approach.

  2015influential citation
• Proton pump inhibitors therapy vs H2 receptor antagonists therapy for upper gastrointestinal bleeding after endoscopy: A meta-analysis.

  2015cites this paper
• Clinical Practice Guidelines on the Diagnosis and Treatment of Gastroesophageal Reflux Disease (GERD)

  2015cites this paper
• Meta‐analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection

  2015cites this paper
• Prescribing Practices and Cost of Drugs for Peptic Ulcer in a Primary Health Center in Pulau Penang, Malaysia

  2013cites this paper
• Indications and safety of proton pump inhibitor drug use in patients with cancer

  2013cites this paper
• A Randomized, Double Blinded, Clinical Trial to Assess the Efficacy and Cost Effectiveness of Omeprazole Compared to Rabeprazole in the Maintenance Therapy of Patients With Gastroesophageal Reflux Disease

  2013cites this paper
• Farmakoterapia krwawienia pochodzenia nieżylakowego z górnego odcinka przewodu pokarmowego

  2013cites this paper
• Mechanisms of wound healing and gastro protective effects of ethanol leaf extract of Jasminum Sambac and Hemigraphis Colorata on HCL/ethanol-induced gastric injury in experimental animals / Ahmed Salim Ahmed Al Rashdi

  2013cites this paper
• Diagnosis and Management of Peptic Ulcer Disease

  2013cites this paper
• PROSPECTIVE SINGLE‐ARM TRIAL OF TWO‐WEEK RABEPRAZOLE TREATMENT FOR ULCER HEALING AFTER GASTRIC ENDOSCOPIC SUBMUCOSAL DISSECTION

  2012cites this paper
• Optimising Acid Inhibition Treatment

  2012cites this paper
• A Multicenter Survey of the Management After Gastric Endoscopic Submucosal Dissection Related to Postoperative Bleeding

  2012cites this paper
• Healing of Oesophagitis

  2012cites this paper
• Guide to the Use of Proton Pump Inhibitors in Adult Patients

  2012cites this paper
• Selection of Proton Pump Inhibitors (PPIs) for Formulary Inclusion Using an Objective Scoring System in Malaysia

  2012cites this paper
• Levels of red blood cell folic acid and a history of peptic ulcer disease

  2012cites this paper
• Krwawienia z przewodu pokarmowego

  2011cites this paper
• In vitro release kinetics study of Esomeprazole Magnesium Trihydrate tablet available in Bangladesh and comparison with the originator brand (Nexium

  2011cites this paper
• Patient Adherence in the Treatment of Gastroesophageal Reflux Disease: Proton Pump Inhibitors Versus Histamine-2 Receptor Antagonists

  2011cites this paper
• Proton pump inhibitors in the management of gastroesophageal reflux disease.

  2011cites this paper
• Five-Year Examination of Utilization and Drug Cost Outcomes Associated with Benefit Design Changes Including Reference Pricing for Proton Pump Inhibitors in a State Employee Health Plan

  2011cites this paper
• Gastrointestinal bleeding.

  2011cites this paper
• Performance of Narrow Band Imaging and Magnification Endoscopy in the Prediction of Therapeutic Response in Patients With Gastroesophageal Reflux Disease

  2011cites this paper
• A systematic review of interventions to facilitate ambulatory laparoscopic cholecystectomy.

  2011cites this paper
• Czy jest nam potrzebny esomeprazol ? Do we need esomeprazole ?

  2010cites this paper
• Gastric Acid-Related Diseases: Focus on Esomeprazole

  2010cites this paper
• The pharmacological therapy of non-variceal upper gastrointestinal bleeding.

  2010cites this paper
• Acquired hyperplastic gastric polyps after treatment of ulcer.

  2010cites this paper
• Czy jest nam potrzebny esomeprazol

  2010cites this paper
• Principes d'usage optimal des inhibiteurs de la pompe à protons (IPP) [ressource électronique]

  2010cites this paper
• H+/K+ ATPase inhibitors in the treatment of acid-related disorders.

  2009cites this paper
• Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis.

  2009cites this paper
• Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety.

  2009cites this paper
• ACID REFLUX AND ULCER DISEASE

  2009cites this paper
• A physician-friendly alternative to prior authorization for prescription drugs.

  2009cites this paper
• Systematic review: standard‐ and double‐dose proton pump inhibitors for the healing of severe erosive oesophagitis – a mixed treatment comparison of randomized controlled trials

  2009cites this paper
• Current and Prospective Pharmacotherapies in Gastroesophageal Reflux Disease

  2009cites this paper
• Management Strategy for Patients With Gastroesophageal Reflux Disease: A Comparison Between Empirical Treatment With Esomeprazole and Endoscopy-Oriented Treatment

  2008cites this paper
• Non-variceal upper gastrointestinal bleeding--guidelines on management.

  2008cites this paper
• Wytyczne postępowania w krwawieniu z górnego odcinka przewodu pokarmowego pochodzenia nieżylakowego

  2008cites this paper
• A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD)

  2007cites this paper
• Peptic ulcer disease.

  2007cites this paper
• Impact of Treatment of Gastroesophageal Reflux on Obstructive Sleep Apnea-Hypopnea Syndrome

  2007cites this paper
• Standard doses of the oral proton pump inhibitors are clinically equivalent: A comparison

  2007cites this paper
• A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis.

  2007cites this paper
• Medical management of gastroesophageal reflux disease

  2007cites this paper
• Prilosec OTC: Sometimes it all comes down to cost.

  2006cites this paper
• Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials.

  2006cites this paper
• Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis – a comparison of esomeprazole with other PPIs

  2006cites this paper
• Perioperative acute upper gastrointestinal haemorrhage in older patients with hip fracture: incidence, risk factors and prevention

  2006cites this paper
• A FREE CONTINUING EDUCATION LESSON Update on the Management of Acid-Related Disorders : A Canadian Perspective

  2006cites this paper
• A 30-Month Evaluation of the Effects on the Cost and Utilization of Proton Pump Inhibitors From Adding Omeprazole OTC to Drug Benefit Coverage in a State Employee Health Plan

  2006cites this paper
• [Reflux esophagitis].

  2005cites this paper
• Current medical management of gastroesophageal reflux disease.

  2005cites this paper
• Developments in the inhibition of gastric acid secretion

  2005cites this paper
• Esomeprazole‐induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: Evidence from clinical and pharmacokinetic data

  2005cites this paper
• Laryngopharyngeal Reflux: Prospective Cohort Study Evaluating Optimal Dose of Proton‐Pump Inhibitor Therapy and Pretherapy Predictors of Response

  2005cites this paper
• Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study

  2005cites this paper
• Evidence-based recommendations for short- and long-term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool.

  2005cites this paper
• Validation of a short questionnaire in English and French for use in patients with persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: the PASS (Proton pump inhibitor Acid Suppression Symptom) test.

  2005cites this paper
• Treatment of uncomplicated reflux disease.

  2005cites this paper
• Patient Acceptance and Economic Outcomes of Rabeprazole Therapy — A Pharmacist-Initiated Interchange Protocol

  2005cites this paper
• Treatment of Gastroesophageal Reflux Disease in Adults: An Individualized Approach

  2004cites this paper
• Impiego degli Inibitori della Pompa protonica (IPP) in Piemonte: indagine sulle abitudini prescrittive dei Medici di Medicina Generale

  2004cites this paper
• Injection therapy of the lower esophageal sphincter for the treatment of GERD.

  2004cites this paper
• Other articles noted

  2004cites this paper
• Gastroesophageal reflux

  2004cites this paper
• Evidence-based assessment of the efficacy of esomeprazole for the healing of erosive esophagitis

  2004cites this paper
• Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor.

  2004cites this paper
• Effects on the Cost and Utilization of Proton Pump Inhibitors From Adding Over-the Counter Omeprazole to Drug Benefit Coverage in a State Employee Health Plan

  2004cites this paper